Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort

被引:15
|
作者
Dauby, Solene [1 ,2 ]
Dive, Dominique [1 ]
Lutteri, Laurence [4 ]
Andris, Cecile [3 ]
Hansen, Isabelle [1 ]
Maquet, Pierre [1 ,2 ]
Lommers, Emilie [1 ,2 ]
机构
[1] CHU Liege, Univ Hosp Liege, Clin Neuroimmunol Unit, Dept Neurol, Liege, Belgium
[2] Univ Liege, GIGA CRC Vivo Imaging, Liege, Belgium
[3] Univ Hosp Liege, Ophthalmol Dept, Clin Ophthalmol Unit, Liege, Belgium
[4] Univ Hosp Liege, Clin Chem Dept, Liege, Belgium
关键词
Neuromyelitis optica; MOG-associated disorders; AQP4-antibody NMO spectrum disorders; Optic neuritis; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; OPTICA SPECTRUM DISORDERS; NEUROMYELITIS-OPTICA; CLINICAL PRESENTATION; TREATMENT RESPONSES; IGG; ANTIBODY; NEURITIS; MULTICENTER; AQUAPORIN-4;
D O I
10.1007/s13760-021-01712-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To emphasize physio-pathological, clinical and prognosis differences between conditions causing serious and sometimes very similar clinical manifestations: anti-aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies related diseases, and seronegative NMOSD (neuromyelitis optica spectrum disorders). Based on Wingerchuk et al. (Neurology 85:177-189, 2015) criteria for NMOSD and on those more recently proposed by Jarius et al. (J Neuroinflammation 15:134, 2018) for MOGAD (MOG associated disorders), we retrospectively surveyed 10 AQP4-NMOSD, 8 MOGAD and 2 seronegative NMOSD, followed at the specialized neuroimmunology unit of the CHU Liege. Female predominance was only observed in AQP4 group. Age at onset was 37.8 and 27.7 years old for AQP4-NMOSD and MOGAD, respectively. In both groups, the first clinical event most often consisted of optic neuritis (ON), followed by isolated myelitis. Fifteen of our 20 patients encountered a relapsing course with 90% relapses in AQP4-NMOSD, 62.5% in MOGAD and 50% in the seronegative group, and a mean period between the first and second clinical event of 7.1 and 4.8 months for AQP4-NMOSD and MOGAD, respectively. In total, we counted 54 ON, with more ON per patient in MOGAD. MOG-associated ON mainly affected the anterior part of the optic nerve with a papilledema in 79.2% of cases. Despite a fairly good visual outcome after MOG-associated ON, retinal nerve fibre layer (RNFL) thickness decreased, suggesting a fragility of the optic nerve toward further attacks. As observed in larger cohorts, our MOGAD and AQP4-NMOSD cases differ by clinical and prognostic features. A better understanding of these diseases should encourage prompt biological screening and hasten proper diagnosis and treatment.
引用
收藏
页码:135 / 144
页数:10
相关论文
共 50 条
  • [31] The landscape of PBMCs in AQP4-IgG seropositive NMOSD and MOGAD, assessed by high dimensional mass cytometry
    Yao, Mengyuan
    Wang, Wenjing
    Sun, Jiali
    Guo, Tianshu
    Bian, Jiangping
    Xiao, Fuyao
    Li, Yuanyuan
    Cong, Hengri
    Wei, Yuzhen
    Zhang, Xinghu
    Liu, Jianghong
    Yin, Linlin
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (02)
  • [32] The Role of Surveillance MRI in Paediatric-onset MOGAD and NMOSD: A Retrospective Cohort Study
    Shah, Paridhi
    Pizoli, Carolyn
    Zebrack, Jane
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1099 - 1099
  • [33] Biopsy Proven Aqp4-Ig G Seronegative Nmosd Case: Benign Course with No Treatment
    Altintas, A.
    Akinci, Y.
    Kaya, Z. E.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 420 - 420
  • [34] A challenging case of a AQP-4-seronegative, anti-MOG positive, NMOSD patient.
    Karageorgiou, Clementine
    Giannouli, Ermioni
    NEUROLOGY, 2017, 88
  • [35] Smoking status and vascular risk factors as predictors of visual disability in AQP4-Neuromyelitis Optica spectrum disorders (AQP4-NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD): A large observational study in the U.K
    Chan, Fiona
    Berhanu, David
    Francis, Anna
    Leite, Maria Isabel
    Geraldes, Ruth
    Palace, Jacqueline
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 130 - 131
  • [36] Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence
    Soares-dos-Reis, Ricardo
    Tsz-Ching, Jessica Li
    Kim, Su-Hyun
    Jacob, Anu
    Whittam, Daniel
    Berthelot, Emeline
    Paul, Friedemann
    Nakashima, Ichiro
    Tye, Janis Siew Noi
    De Seze, Jerome
    Jitprapaikulsan, Jiraporn
    Tan, Kevin
    Yang, Li
    Elsone, Liene
    Leite, Maria Isabel
    Mealy, Maureen A.
    Levy, Michael
    Fan, Moli
    Siebert, Nadja
    Asgari, Nasrin
    Cabre, Philippe
    Siritho, Sasitorn
    Pittock, Sean J.
    Wing-Ho, Stephen Cheng
    Senger, Thomas
    Yeo, Tianrong
    Takai, Yoshiki
    Pandit, Lekha
    Kim, Ho Jin
    Palace, Jacqueline
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 53
  • [37] Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD
    Kaneko, Kimihiko
    Kuroda, Hiroshi
    Matsumoto, Yuki
    Sakamoto, Naohiro
    Yamazaki, Naoya
    Yamamoto, Naoki
    Umezawa, Shu
    Namatame, Chihiro
    Ono, Hirohiko
    Takai, Yoshiki
    Takahashi, Toshiyuki
    Fujimori, Juichi
    Nakashima, Ichiro
    Harigaya, Yasuo
    Lassmann, Hans
    Fujihara, Kazuo
    Misu, Tatsuro
    Aoki, Masashi
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2024, 11 (05):
  • [38] Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD
    Wang, Lei
    Xia, Ruihong
    Li, Xiangliang
    Shan, Jingli
    Wang, Shengjun
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [39] Study of sleep abnormalities in patients with neuromyelitis optica spectrum disorder - aqp-4, seronegative nmosd and mog associated disorders
    Oommen, A.
    Yadav, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 478 - 479
  • [40] The burden of psychiatric morbidity in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD before and after neurological diagnosis
    Tan, Yin Yin
    Saffari, Seyed Ehsan
    Tye, Janis Siew Noi
    Peng, Xuejuan
    Koh, Min Jie
    Mahmood, Abu Bakar Shakran Bin
    Tan, Jeanne May May
    Tan, Kevin
    Yeo, Tianrong
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89